1. Market Research
  2. > Pathology
67 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • Gilead Sciences, Inc.

NHL: Follicular lymphoma

  • $ 5000
  • April 2016
  • 252 pages

NHL: Follicular lymphoma Disease Coverage | Treatment: Follicular Lymphoma practices.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Gilead Sciences, Inc.

Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025

  • $ 3500
  • August 2020
  • 266 pages

IN MAY 2018, THE PRODUCT RECEIVED EXPANDED INDICATION APPROVAL FOR B-CELL LYMPHOMA.

  • Gene Therapy
  • Lymphoma
  • Therapy
  • World
  • Gilead Sciences, Inc.

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • Gilead Sciences, Inc.

Global Regenerative Medicine Market - Opportunities and Forecast

  • $ 2400
  • August 2019
  • 326 pages

This strategic acquisition will further promote Gilead as an industry leader in refractory large B-cell lymphoma after two or more lines of therapy.

  • Biopharmaceutical
  • Lymphoma
  • Regenerative Medicine
  • Market Size
  • Gilead Sciences, Inc.

Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Technology ; Application

  • $ 4550
  • April 2020
  • 177 pages

The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. The growth of ...

  • Drug Delivery
  • Lymphoma
  • Topical Delivery
  • Forecast
  • Gilead Sciences, Inc.

Global Sterile Injectables Market – Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2023 - Molecule Type, Drug Type, Indication, Channel

  • $ 2400
  • June 2018
  • 240 pages

lymphoma Diffuse large B-cell lymphoma Diffuse large B-cell lymphoma Pfizer Utomilumab Human IgG## CD## Phase ## Hoffmann-La Roche Polatuzumab vedotin Humanized IgG## ADC CD##b Phase ## Viventia Bio Oportuzumab monatox Humanized scFv immunotoxin EpCAM Phase ## Bladder cancer S

  • Endocrine Disease
  • Lymphoma
  • World
  • Baxter International Inc.
  • Gilead Sciences, Inc.

Gilead Sciences Inc: Coronavirus Disease 2019 (COVID-19) Company Impact

  • $ 495
  • May 2020
  • 32 pages

GILEAD IS EXPECTING APPROVAL OF KTEX-## (CAR-T CELL TARGETING CD##) AT THE END OF 2020 FOR MANTLE CELL LYMPHOMA.

  • Clinical Trial
  • Lymphoma
  • Pathology
  • World
  • Gilead Sciences, Inc.

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • January 2019
  • 201 pages

ALTHOUGH CELLTRION' S TRUXIMA WAS SIMILARLY TREATED BY THE FDA, THE COMPANY COMPLIED WITH REQUESTS FOR ADDITIONAL DATA AND IN NOVEMBER 2018, CELLTRION' S TRUXIMA WAS APPROVED, BUT ONLY FOR THE TREATMENT OF B-CELL NON-HODGKIN AND FOLLICULAR LYMPHOMAS (CELLTRION, PRESS RELEASE, ## NOV

  • Biosimilar
  • Hospital
  • Lymphoma
  • Therapy
  • Gilead Sciences, Inc.

Chimeric Antigen Receptor Cell Therapy

  • $ 7995
  • February 2019
  • 108 pages

This doesn' t appear, to me, to be a major game-changer, at least for lymphoma.

  • Cell Therapy
  • Immunotherapy
  • Lymphoma
  • Gilead Sciences, Inc.
  • Novartis AG

Oncology Drugs Market Global Briefing 2018

  • $ 1000
  • January 2018
  • 38 pages

THIS SHARE ATTRIBUTES TO LARGE POPULATION OF CANCER PATIENTS SUFFERING FROM VARIOUS TYPES OF BLOOD CANCERS SUCH AS LEUKEMIA, LYMPHOMA, AND MYELOMA.

  • Lymphoma
  • Oncology
  • Therapy
  • World
  • Gilead Sciences, Inc.

Oncology Drug Report: Zydelig | Idelalisib – 2011 -2016 analysis; 2017-2021 expectations

  • $ 308
  • January 2017
  • 52 pages

LONG-TERM DATA IN CLL kemia, follicular lymphoma and small lymphocytic lymphoma: PRESS RELEASE ## ## Sep 2014 European Commission grants Marketing Authorization for Gilead' s Zydelig® (idelalisib) for the treatment of chronic lymphocytic leukemia and follicular

  • Lymphoma
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • Roche Group

Gene Therapy Market - Growth, Trends, and Forecast (2019 - 2024)

  • $ 4250
  • September 2019
  • 113 pages

In March 2018, Novartis received the approval to sell its Kymriah CAR-T gene therapy in Japan for USD ##, ##, to treat acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

  • Gene Therapy
  • Lymphoma
  • United States
  • Amgen Inc.
  • Gilead Sciences, Inc.

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU

  • $ 7995
  • September 2018
  • 162 pages

It is indicated for adult patients with R/ R DLBCL and primary mediastinal large B-cell lymphoma (PMBCL).

  • Cancer
  • Lymphoma
  • Oncology
  • Pharmaceutical
  • Gilead Sciences, Inc.

Pharmaceutical Drugs Global Market Report 2018

  • $ 8000
  • March 2018
  • 455 pages

Its importance results from the large population of cancer patients suffering from various types of blood cancers such as leukemia, lymphoma, and myeloma.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Market Size
  • Gilead Sciences, Inc.

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • November 2018
  • 151 pages

ET AL. (2008) ' COMORBID CONDITIONS AND SURVIVAL IN UNSELECTED, NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA', LEUKEMIA AND LYMPHOMA, ##(##), PP. ##-##.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Gilead Sciences, Inc.

Global Liver Disease Treatment Market 2017-2021

  • $ 2500
  • July 2017
  • 98 pages

TECHNAVIO.

  • Digestive System Disorder
  • Therapy
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

  • $ 4995
  • September 2017
  • 155 pages

THE FOURTH CHAPTER ANALYZES THE RESPIRATORY DISORDERS PIPELINE, DETAILING, AMONG OTHER PARAMETERS, DRUG DISTRIBUTION BY STAGE OF DEVELOPMENT, MOLECULE TYPE AND MOLECULAR TARGET, PLUS AN ANALYSIS OF THE KEY INDICATIONS IN THE PIPELINE: LEUKEMIA, LYMPHOMA AND MYELOMA.

  • Lymphoma
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Gilead Sciences, Inc.

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Canada

  • $ 1995
  • July 2017
  • 228 pages

lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-##) Relapsed/ refractory patients with indolent non-Hodgkin' s lymphoma in combination with Bendamustine and Rituximab or R-CHOP (randomized study FLR-##) Newly diagnosed non-germinal center B-cell sub

  • Healthcare
  • Lymphoma
  • Medical Equipment
  • Pharmaceutical
  • Gilead Sciences, Inc.

Global Cystic Fibrosis Therapeutics Market 2018-2022

  • $ 2500
  • January 2018
  • 111 pages

Awards and recognitions Product launches In November 2017, the FDA approved Gazvya in combination with chemotherapy for patients with previously untreated advanced follicular lymphoma.

  • Lymphoma
  • Therapy
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
View report >

Hospital Forecast Statistics in the US

  • December 2017
  • 34 pages

GOV CHART ##: LYMPHOMA & NON-ACUTE LEUKEMIA W/ MAJOR COMPLICATIONS OR COMORBIDITIES CHART ##: LYMPHOMA & NON-ACUTE LEUKEMIA W/ MAJOR COMPLICATIONS OR COMORBIDITIES (CONTINUED) CHART ##: LYMPHOMA & NON-ACUTE LEUKEMIA W/ COMPLICATION OR COMORBIDITI

  • Hospital
  • Lymphoma
  • United States
  • Gilead Sciences, Inc.
  • Jefferies LLC

Therapy Market January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on